PYX Resources: Achieving volume and diversification milestones. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,775.00
Bid: 1,771.00
Ask: 1,771.50
Change: -8.50 (-0.48%)
Spread: 0.50 (0.028%)
Open: 1,773.50
High: 1,779.00
Low: 1,764.50
Prev. Close: 1,783.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LIVE MARKETS-U.S. tax hike less likely: a boon for Europe Inc too

Thu, 05th Nov 2020 10:08

* European shares open higher led by tech

* Strong Q3 earnings reports also help

* Bank of England ramps up stimulus

* Wall Street futures point to more gains
Welcome to the home for real-time coverage of markets brought to you by Reuters reporters. You
can share your thoughts with us at markets.research@thomsonreuters.com

U.S. TAX HIKE LESS LIKELY: A BOON FOR EUROPE INC TOO (0957 GMT)

A gridlock in Washington with Biden president and Republicans retaining the Senate is a
scenario that's becoming more likely and equity investors are starting to appreciate the lower
likelihood of business unfriendly policy.

And the possible benefits for corporates, especially on the tax front, are going to be felt
on both sides of the pond.

"President Trump cut the U.S. corporation tax rate from 35% to 21%. The Democrats were
intending to raise it back to 28%. That prospect now seems less likely, which should help U.S.
equities," say Citi strategists.

"It should also boost non-US companies with significant US businesses. Their relative
performance has flat-lined recently," they added.

Several shares in European companies with big presence in the U.S. are doing relatively well
since it emerged that Trump was doing better than expected by the polls.

In the snapshot you can see today's price moves of a basket of European stocks with high
revenue exposure to North America. The basket, which includes names such as Deutsche Telekom
, UBS, Roche and National Grid, is courtesy of Citi.

(Danilo Masoni)

*****

OPENING SNAPSHOT: STRONG Q3, TECH RALLY AND MORE UK STIMULUS (0854 GMT)

European bourses are well in positive territory supported by a batch of positive Q3 results
and more stimulus in the UK as the country starts a second national lockdown.

The pan-European STOXX 600 index is up 0.8% to its highest level since Oct. 20,
with the tech sector leading the gains, up 2.5%.

Britain's blue chips are up 0.3% after the Bank of England increased its already
huge bond-buying stimulus by a bigger-than-expected 150 billion pounds to 895 billion pounds.
The BoE kept the bank rate at 0.1%.

In terms of single companies, Milan-listed Tenaris is set for its best day in 9
years after reporting strong Q3 results, it was last up more than 11%.

(Joice Alves)

*****

ON THE RADAR: BANKS Q3, ARCELORMITTAL, SAINSBURY (0746 GMT)

Looking at futures, it seems like it is going to be a start of the day in the black for
European bourses in a data heavy morning, which also sees investors having to digest a slew of
earnings results.

There is a mixed batch of banking Q3 results with France's third-biggest listed bank Societe
Generale swinging back to profit, as its equity trading business continued to recover
from a weak start to the year; and Italy's second-biggest bank UniCredit posted much
higher than expected net profit as Europe emerged from lockdowns.

In the meantime, Germany's Commerzbank swung to a Q3 loss, as the lender undergoes
a restructuring.

ING Groep, the largest Dutch bank, reported lower than expected pre-tax profit of
1.20 billion euros on declining interest income amid the coronavirus pandemic and said it
intends to cut 1,000 jobs.

British supermarket group Sainsbury also said it could cut 3,500 jobs in a
restructuring.

On a brighter note, ArcelorMittal, the world's largest steelmaker, reported Q3 core
profit above expectations as the easing of lockdowns led to improved demand.
German broadcaster ProSiebenSat.1 Media returned to profit, and reinstated its FY
guidance. Its shares rose 5.7% in premarket trade.

HeidelbergCement, the world's No.2 cement maker, posted a 13% increase in Q3 core
profit, as cost cuts helped it to shrug off the impact of the pandemic and forecast higher
earnings for 2020.

Siemens Gamesa keeps profit target as Q4 uptick fails to stave off loss.

British insurer RSA's underwriting profit rose strongly in the first nine months of
2020 due to improvements the company made to its underwriting strategy.

German reinsurance group Munich Re's net profit declined 77% to 199 million euros
in Q3.

Staying in Germany, specialty chemicals maker Lanxess narrowed its 2020 core
profit outlook range after the coronavirus pandemic, saying it was seeing a pick up in the auto
industry, with China and the U.S. also providing positive stimuli.

While Lufthansa said it booked a net loss of 2 billion euros in Q3.

Sunrise Communications announced plans to boost its 2020 dividend to 4.55 and 4.65
Swiss francs per share, from 4.4 francs, ahead of the Swiss telecommunications firm's takeover
by Liberty Global that will lead to its delisting.

(Joice Alves)

*****

MORNING CALL: STILL NO U.S. PRESIDENT (0638 GMT)

Futures are pointing to gains for European bourses this morning mirroring Asian shares,
which climbed on the prospect that a gridlock in the U.S. Congress will give a boost to some
industries.

So far, the count shows that Democratic challenger Joe Biden narrowly ahead in key states,
but the risk of a prolonged contested election remains.

Back in Europe, it will be a data heavy morning with EZ and UK PMI data due.

The Bank of England's November monetary policy decision is also on schedule. The Telegraph
newspaper reported that the central bank is considering a move into negative interest rates.

(Joice Alves)

*****

More News
31 Jan 2024 08:55

LONDON MARKET OPEN: Stocks lack direction ahead of Fed, BoE

(Alliance News) - Stock prices in London lacked direction at the open on Wednesday, as investors nervously look ahead to interest rate decisions from the US Federal Reserve and Bank of England.

Read more
31 Jan 2024 07:46

LONDON BRIEFING: Stocks called up; GSK revenue and profit up

(Alliance News) - Stocks in London are called to open higher, as markets share of nerves around the next set of interest rate decisions.

Read more
29 Jan 2024 08:51

GSK seeks expanded use of RSV vaccine in EU, wins approval for Omjjara

(Alliance News) - GSK PLC on Monday celebrated regulatory progress for two of its products in the EU.

Read more
29 Jan 2024 07:43

LONDON BRIEFING: Superdry looks at saving costs; Ferrexpo loses case

(Alliance News) - Stocks in London are expected to start the week on a cautious note, as investors nervously look ahead to two key interest rate decisions.

Read more
29 Jan 2024 07:07

GSK gets EU approval to sell blood cancer treatment Omijara

(Sharecast News) - Biopharma giant GSK has been given the green light by European regulators to sell Omjjara, its treatment for patients with a rare type of blood cancer.

Read more
26 Jan 2024 10:47

Citi hikes target price for GSK but stays 'neutral'

(Sharecast News) - Shares in biopharma giant GSK were rising on Friday, helped by forecast upgrades from Citi, which raised its target price on the stock from 1,535p to 1,700p.

Read more
24 Jan 2024 15:08

Private equity firm Yellow Wood close to deal to acquire ChapStick-sources

Jan 24 (Reuters) - Private equity firm Yellow Wood Partners is in advanced talks to acquire ChapStick, a lip balm brand, from Haleon Plc, the former consumer health division of drug developer GSK Plc, four people familiar with the matter said.

Read more
24 Jan 2024 14:34

UK earnings, trading statements calendar - next 7 days

Thursday 25 January 
Britvic PLCTrading Statement
Conduit Holdings LtdTrading Statement
CVS Group PLCTrading Statement
Dr Martens PLCTrading Statement
Fevertree Drinks PLCTrading Statement
Foxtons Group PLCFull Year Results
Fuller, Smith & Turner PLCTrading Statement
Halfords Group PLCTrading Statement
Idox PLCFull Year Results
IG Group Holdings PLCHalf Year Results
Intermediate Capital Group PLCTrading Statement
Mitie Group PLCTrading Statement
NCC Group PLCHalf Year Results
Newmark Security PLCHalf Year Results
Next 15 Group PLCTrading Statement
PPHE Hotel Group LtdTrading Statement
Secure Trust Bank PLCTrading Statement
St James's Place PLCTrading Statement
Time Finance PLCHalf Year Results
Titon Holdings PLCFull Year Results
Wizz Air Holdings PLCQ3 Results
Workspace Group PLCTrading Statement
Friday 26 January 
Paragon Banking Group PLCTrading Statement
Record PLCTrading Statement
Superdry PLCHalf Year Results
Taylor Maritime Investments LtdTrading Statement
WH Smith PLCTrading Statement
YouGov PLCTrading Statement
Monday 29 January 
Team Internet Group PLCTrading Statement
Tuesday 30 January 
Diaceutics PLCTrading Statement
Diageo PLCHalf Year Results
Kromek Group PLCHalf Year Results
Luceco PLCTrading Statement
Oxford Cannabinoid Technologies Holdings PLCHalf Year Results
Pets at Home Group PLCTrading Statement
Renewi PLCTrading Statement
Saga PLCTrading Statement
SSP Group PLCTrading Statement
SThree PLCFull Year Results
Synthomer PLCTrading Statement
Wednesday 31 January 
Aberforth Smaller Companies Trust PLCFull Year Results
abrdn Private Equity Opportunities Trust PLCFull Year Results
Ecora Resources PLCTrading Statement
GSK PLCFull Year Results
ITM Power PLCHalf Year Results
NWF Group PLCHalf Year Results
  
Comments and questions to newsroom@alliancenews.com
  
A full 21-day events calendar is provided each day with a subscription to Alliance News UK Professional.
  
Copyright 2024 Alliance News Ltd. All Rights Reserved.

Read more
22 Jan 2024 21:22

Fate of most remaining Zantac lawsuits weighed by Delaware judge

Jan 22 (Reuters) - GSK, Pfizer and other pharmaceutical companies are urging a judge in Delaware this week to find that evidence plaintiffs' lawyers want to use in about 72,000 lawsuits claiming that the discontinued heartburn drug Zantac caused cancer is not supported by science.

Read more
22 Jan 2024 17:08

Fate of most remaining Zantac lawsuits weighed by Delaware judge

Jan 22 (Reuters) - GSK, Pfizer and other pharmaceutical companies will urge a judge in Delaware this week to find that evidence plaintiffs' lawyers want to use in about 72,000 lawsuits claiming that the discontinued heartburn drug Zantac caused cancer is not supported by science.

Read more
22 Jan 2024 09:34

IN BRIEF: Oxford Nanopore appoints Keher to CFO as Cowper becomes COO

Oxford Nanopore Technologies - Oxford, England-based company specialising in nanopore DNA-sequencing - Appoints Nick Keher as chief financial officer and director, effective immediately. Keher will replace Tim Cowper as he moves into a new role as Oxford Nanopore's chief operating officer. The company says that Cowper has been performing the majority of COO duties for the past five years, and that he will lead the company's efforts to expand its international footprint. The company also says that new CFO Keher possesses "significant experience of financial leadership of complex, scientific businesses", having served in similar roles at Clinigen Group PLC, BenevolentAI SA, Royal Bank of Canada, Investec PLC and GSK PLC.

Read more
17 Jan 2024 09:38

UPDATE: GSK raises GBP978 million as cuts stake in Haleon to 4.2%

(Alliance News) - GSK PLC early Wednesday confirmed it agreed to sell 300 million shares in Haleon PLC, reducing its remaining stake in the consumer healthcare products spin-off to just 4.2%.

Read more
17 Jan 2024 08:05

GSK raises £978m through Haleon share sale

(Sharecast News) - GSK said on Wednesday that it has raised around £978m from the sale of shares in Haleon.

Read more
17 Jan 2024 07:46

LONDON BRIEFING: UK inflation surprises as unexpectedly rises to 4.0%

(Alliance News) - Stocks in London are called to open lower on Wednesday, following some hotter-than-expected consumer price data from the UK.

Read more
17 Jan 2024 07:31

GSK raises $1.24 bln from latest Haleon stake sale

Jan 17 (Reuters) - GSK has raised 978 million pounds ($1.24 billion) from a discounted sale of a stake in its spun-off consumer healthcare business Haleon, the British drugmaker said on Wednesday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.